Skip to main content
Clinical Trials/NCT02574572
NCT02574572
Unknown
Phase 1

Evaluation of the Safety and Potential Effectiveness of Autologous Mesenchymal Stem Cells Transplantation in Subjects With Cervical Chronic and Complete Spinal Cord Injury

Hospital Sao Rafael1 site in 1 country10 target enrollmentSeptember 6, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Spinal Cord Injury
Sponsor
Hospital Sao Rafael
Enrollment
10
Locations
1
Primary Endpoint
Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to analyze the safety and efficacy of autologous bone marrow mesenchymal stem cell transplantation in patients with cervical chronic and complete spinal cord injury.

Detailed Description

This is a pilot, phase I study, in a prospective cohort. The study population will consist of 10 patients who had spinal cord injury for at least 12 months, with cervical chronic and complete spinal cord injury, ASIA grade A. A practitioner, a surgeon and a nurse will review the medical records of the patients to determine the presence / absence of inclusion / exclusion criteria. If the patient is a potential candidate for the study, an interview will be scheduled to review and confirm his/her eligibility. Patients will undergo a series of clinical and neurological assessments and will also be submitted to the following procedures: * Cell blood count; * Biochemical analysis (measurement of electrolytes - sodium, potassium, magnesium); * Renal function tests (urea and creatinine); * Liver function tests; * Coagulation profile; * Metabolic profile (glucose, total cholesterol and fractions); * Urine summary and culture; * Serology required for blood transfusion and marrow transplant in Brazil; * Electrocardiogram; * Chest X-Ray; * Bone densitometry; * Urodynamic studies; * Somatosensory evoked potential; * Computed tomography of thoracic and lumbar spine; * Magnetic resonance imaging of the thoracic and lumbar spine. Also as part of the preoperative evaluation, the patients will respond to questions from the SF (Short Form) -36 questionnaire (for assessment of quality of life) and the questionnaires for the assessment of neuropathic pain. Clinical follow-up will be kept for patients who suspend their participation in the study for any adverse event and / or laboratory abnormality, or for the patient's own desire, following insurance protocols. In addition to the clinical and surgical follow-up, specific medical care will be offered to patients who experience adverse events, until stabilization of the patient, even if the target date for completion of the study has been exceeded. The candidates included in the study will be asked to voluntarily participate and give their informed written consent.

Registry
clinicaltrials.gov
Start Date
September 6, 2017
End Date
June 30, 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ricardo Ribeiro dos Santos

PhD

Hospital Sao Rafael

Eligibility Criteria

Inclusion Criteria

  • Blunt spinal cord injury at cervical level, between C5 and C7, or penetrating spinal cord injury, at the same level, provided that the mechanism of injury had been spinal shock, ischemia or hematoma, with at least 12 months of injury;
  • ASIA grade A;
  • Signing of the written consent.

Exclusion Criteria

  • Spinal cord injuries by sharp objects, firearms, and not traumatic or congenital causes, even if at different levels of the spinal cord;
  • Concomitant brain injuries;
  • Diabetes mellitus type 1 or 2 as defined by fasting glucose above 126 mg / use of medication and medical history;
  • Infectious processes in acute and / or chronic course, confirmed by additional tests and / or medical history;
  • Immunodeficiency, autoimmune diseases and neoplastic processes, confirmed by additional tests and / or medical history;
  • Terminal, neurodegenerative, primary hematologic and musculoskeletal diseases confirmed by additional tests and / or past medical history;
  • Osteopathies reflecting increased risk for bone marrow puncture;
  • Coagulopathies;
  • Severe organ failure (heart, kidney or liver), confirmed by additional tests or medical history;
  • Pregnancy or lactation;

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging

Time Frame: 12 months

Secondary Outcomes

  • Functional improvement in ASIA (American Spinal Injury Association) grade(12 months)
  • Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)(12 months)
  • Improvements in sensorial mapping and neuropathic pain(12 months)

Study Sites (1)

Loading locations...

Similar Trials